Immune globulin - Green Cross

Drug Profile

Immune globulin - Green Cross

Alternative Names: GC-5101B; GC5107; GC5107A; I.V.-Globulin SN inj.; IVIG 10%

Latest Information Update: 16 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Green Cross
  • Class Immunoglobulins; Immunoproteins; Serum globulins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Agammaglobulinaemia; Guillain-Barre syndrome; Infections; Mucocutaneous lymph node syndrome
  • Preregistration Immunodeficiency disorders
  • Phase III Thrombocytopenia

Most Recent Events

  • 03 Dec 2016 Efficacy, pharmacokinetc and adverse event data from a phase III trial in Thrombocytopenia presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-2016)
  • 01 Jun 2016 Green Cross initiates enrolment in a phase III trial for Immunodeficiency disorders in Canada (NCT02783482)
  • 30 Apr 2016 Green Cross completes a phase III trial of immune globulin 10% for Thrombocytopenia in South Korea (NCT02063789)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top